Anti-infective carbonic anhydrase inhibitors: A patent and literature review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 6, 2013, Pages 693-704

  Capasso, Clemente ^a   Supuran, Claudiu T ^b  

^a INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anti infective; Bacteria; Carbonic anhydrase inhibitor; Fungi; Protozoa; Sulfonamide

Indexed keywords

ACETAZOLAMIDE; ANTIINFECTIVE AGENT; BENZOLAMIDE; BICARBONATE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CELECOXIB; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; INDISULAM; METHAZOLAMIDE; SULFONAMIDE; SULPIRIDE; TOPIRAMATE; VALDECOXIB; ZONISAMIDE;

BRUCELLA; DRUG MECHANISM; GENOME; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HUMAN; METHANOSARCINA THERMOPHILA; METHANOTHERMOBACTER THERMAUTOTROPHICUS; MOLECULAR CLONING; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; NEISSERIA SICCA; NONHUMAN; REVIEW; SALMONELLA ENTERICA; STREPTOCOCCUS PNEUMONIAE; VIBRIO CHOLERAE;

ANIMALS; ANTI-INFECTIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HUMANS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; SULFONAMIDES;

EID: 84878041301     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.778245     Document Type: Review

References (110)

1. Tibayrenc M, Ayala FJ. Reproductive clonality of pathogens: a perspective on pathogenic viruses, bacteria, fungi, and parasitic protozoa. Proc Natl Acad Sci USA 2012;109:E3305-13
2. Roux O, Cereghino R, Solano PJ, et al. Caterpillars and fungal pathogens: two co-occurring parasites of an ant-plant mutualism. PLoS One 2011;6:e20538
3. Joyce SA, Watson RJ, Clarke DJ. The regulation of pathogenicity and mutualism in Photorhabdus. Curr Opin Microbiol 2006;9:127-32
4. Soto W, Punke EB, Nishiguchi MK. Evolutionary perspectives in a mutualism of sepiolid squid and bioluminescent bacteria: combined usage of microbial experimental evolution and temporal population genetics. Evolution 2012;66:1308-21
5. Cardoso T, Ribeiro O, Aragao IC, et al. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis 2012;12:375
6. Cox GM, Mukherjee J, Cole GT, et al. Urease as a virulence factor in experimental cryptococcosis. Infect Immun 2000;68:443-8
7. Cox GM, McDade HC, Chen SC, et al. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol 2001;39:166-75
8. Bostanci N, Belibasakis GN. Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen. FEMS Microbiol Lett 2012;333:1-9
9. Alp S. Putative virulence factors of Aspergillus species. Mikrobiyol Bul 2006;40:109-19
10. Schaller M, Borelli C, Korting HC, et al. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 2005;48:365-77
11. Krungkrai SR, Suraveratum N, Rochanakij S, et al. Characterisation of carbonic anhydrase in Plasmodium falciparum. Int J Parasitol 2001;31:661-8
12. Sein KK, Aikawa M. The pivotal role of carbonic anhydrase in malaria infection. Med Hypotheses 1998;50:19-23
13. Joseph P, Ouahrani-Bettache S, Montero JL, et al. A new beta-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorg Med Chem 2011;19:1172-8
14. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81
15. Smith KS, Ferry JG. Prokaryotic carbonic anhydrases. FEMS Microbiol Rev 2000;24:335-66
16. Maeda S, Price GD, Badger MR, et al. Bicarbonate binding activity of the CmpA protein of the cyanobacterium Synechococcus sp. strain PCC 7942 involved in active transport of bicarbonate. J Biol Chem 2000;275:20551-5
17. Joseph P, Turtaut F, Ouahrani-Bettache S, et al. Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. J Med Chem 2010;53:2277-85
18. Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34
19. Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malaria parasite and its inhibition. Curr Pharm Des 2008;14:631-40
20. Reungprapavut S, Krungkrai SR, Krungkrai J. Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy. J Enzyme Inhib Med Chem 2004;19:249-56
21. Bertucci A, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. Bioorg Med Chem Lett 2011;21:710-14
22. Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin Ther Pat 2012;22:79-88
23. Supuran C, Benedini F, Biondi S, et al. Nitrate esters of carbonic anhydrase inhibitors. WO071421; 2008
24. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-9
25. Aggarwal M, McKenna R. Update on carbonic anhydrase inhibitors: a patent review (2008-2011). Expert Opin Ther Patents 2012;22:903-15
26. Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421-68
27. Ilies MA, Masereel B, Rolin S, et al. Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorg Med Chem 2004;12:2717-26
28. Thiry A, Dogne J-M, Supuran CT, et al. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des 2008;14:661-71
29. Wang L-H, Huang C-T. Process for the preparation and purification of topiramate. TW201127842; 2011
30. Zuo X, Yang Y, Zou X, et al. Method for producing topiramate. CN101450951; 2009
31. Berkner JE, Duncan S, Mills J. Process for the preparation of anticonvulsant derivatives of topiramate. HK1088336; 2008
32. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767-77
33. Supuran CT, Parkkila S. Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms. WO139678; 2010
34. Ebbesen P, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors. WO098610; 2011
35. Supuran C, Dedhar S, McDonald P, et al. Novel sulfonamide compounds for inhibition of metastatic tumor growth. WO021963; 2012
36. Supuran C, Dedhar S, Carta F, et al. Carbonic anhydrase inhibitors with antimetastatic activity. WO070024; 2012
37. Masereel B, Frederick R, Supuran CT. Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders. WO175654; 2012
38. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759-72
39. Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011;54:8271-7
40. Liu F, Martin-Mingot A, Lecornue F, et al. Carbonic Anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry. J Enzyme Inhib Med Chem 2012;27:886-91
41. Kappers J, Hearn JM, Qui R. Therapeutic compositions and methods for treating gram-negative bacterial infections. US0038917; 2011
42. Winum J-Y, Montero J-L, Kohler S. Histidinol dehydrogenase inhibitors, and use thereof as medicaments. US0129907; 2012
43. Tanzer M, Shuster JR, Hamer L, et al. Methods for the identification of inhibitors of histidinol dehydrogenase as antibiotics. WO089156; 2005
44. Patten PA, Armstrong ES. Combinations comprising a LpxC inhibitor and an antibiotic for use in the treatment of infections caused by gram negative bacteria. WO005355; 2011
45. Siddiqui MA, Mansoor UF, Reddy PA, Madison PS. Compounds for the treatment of inflamatory disorders and microbial diseases. WO064732; 2007
46. Takashima H, Yoshinaga M, Ushiki Y, et al. Novel hydroxamic acid derivatives. WO105515; 2008
47. Takashima H, Suga Y, Urabe H, et al. Novel hydroxamic acid derivatives having naphthyridine N-oxide. WO024356; 2010
48. Takashima H, Tsuruta R, Yabiuuchi T, et al. Novel hydroxamic acid derivative. WO132712; 2011
49. Reddy PAP, Mansoor UF, Siddiqui MA. Synthesis and use of antibacterial agents. US0212078; 2011
50. Woese CR, Kandler O, Wheelis ML. Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eukarya. Proc Natl Acad Sci USA 1990;87:4576-9
51. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
52. Adler L, Brundell J, Falkbring SO, et al. Carbonic anhydrase from Neisseria sicca, strain 6021. I. Bacterial growth and purification of the enzyme. Biochim Biophys Acta 1972;284:298-310
53. Chirica LC, Elleby B, Jonsson BH, et al. The complete sequence, expression in Escherichia coli, purification and some properties of carbonic anhydrase from Neisseria gonorrhoeae. Eur J Biochem 1997;244:755-60
54. Chirica LC, Petersson C, Hurtig M, et al. Expression and localization of alpha-and beta-carbonic anhydrase in Helicobacter pylori. Biochim Biophys Acta 2002;1601:192-9
55. Guilloton MB, Korte JJ, Lamblin AF, et al. Carbonic anhydrase in Escherichia coli. A product of the cyn operon. J Biol Chem 1992;267:3731-4
56. Vullo D, Nishimori I, Minakuchi T, et al. Inhibition studies with anions and small molecules of two novel beta-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg Med Chem Lett 2011;21:3591-5
57. Supuran CT. Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Des 2010;16:3233-45
58. Smith KS, Ferry JG. A plant-type (betaclass) carbonic anhydrase in the thermophilic methanoarchaeon Methanobacterium thermoautotrophicum. J Bacteriol 1999;181:6247-53
59. Alber BE, Ferry JG. A carbonic anhydrase from the archaeon Methanosarcina thermophila. Proc Natl Acad Sci USA 1994;91:6909-13
60. De Stefano L, Vitale A, Rea I, et al. Enzymes and proteins from extremophiles as hyperstable probes in nanotechnology: the use of D-trehalose/D-maltose-binding protein from the hyperthermophilic archaeon Thermococcus litoralis for sugars monitoring. Extremophiles 2008;12:69-73
61. Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnologic use for CO2 capture. J Enzyme Inhib Med Chem 2013;28:229-30
62. Nakagawa S, Shtaih Z, Banta A, et al. Sulfurihydrogenibium yellowstonense sp. nov., an extremely thermophilic, facultatively heterotrophic, sulfur-oxidizing bacterium from Yellowstone National Park, and emended descriptions of the genus Sulfurihydrogenibium, Sulfurihydrogenibium subterraneum and Sulfurihydrogenibium azorense. Int J Syst Evol Microbiol 2005;55:2263-8
63. Vullo D, De Luca V, Scozzafava A, et al. The first activation study of a bacterial carbonic anhydrase (CA). The thermostable alpha-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines. Bioorg Med Chem Lett 2012;22:6324-7
64. Vullo D, Luca VD, Scozzafava A, et al. The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides. Bioorg Med Chem 2013;21:1534-8, http://dx.doi.org/10.1016/j. bmc.2012.07.024
65. De Luca V, Vullo D, Scozzafava A, et al. Anion inhibition studies of an alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP. Bioorg Med Chem Lett 2012;22:5630-4
66. Capasso C, De Luca V, Carginale V, et al. Biochemical properties of a novel and highly thermostable bacterial alpha-carbonic anhydrase from Sulfurihydrogenibium yellowstonense YO3AOP. J Enzyme Inhib Med Chem 2012;27:892-7
67. Akdemir A, Vullo D, Luca VD, et al. The extremo-alpha-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines. Bioorg Med Chem Lett 2013;23:1087-90
68. De Luca V, Vullo D, Scozzafava A, et al. An alpha-carbonic anhydrase from the thermophilic bacterium Sulphurihydrogenibium azorense is the fastest enzyme known for the CO(2) hydration reaction. Bioorg Med Chem 2013: In press
69. Vullo D, De Luca V, Scozzafava A, et al. Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense. Bioorg Med Chem Lett 2012;22:7142-5
70. Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem 2006;49:2117-26
71. Nishimori I, Minakuchi T, Kohsaki T, et al. Carbonic anhydrase inhibitors. The beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett 2007;17:3585-94
72. Cronk JD, Rowlett RS, Zhang KY, et al. Identification of a novel noncatalytic bicarbonate binding site in eubacterial beta-carbonic anhydrase. Biochemistry 2006;45:4351-61
73. Suarez Covarrubias A, Larsson TA, Hogbom M, et al. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J Biol Chem 2005;280:18782-9
74. Suarez Covarrubias A, Bergfors T, Jones TA, et al. Structural mechanics of the pH-dependent activity of the beta-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem 2006;28:4993-9
75. Minakuchi T, Nishimori I, Vullo D, et al. Molecular cloning, characterization and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J Med Chem 2009;52:2226-32
76. Nishimori I, Minakuchi T, Vullo D, et al. Carbonic anhydrase inhibitors. cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem 2009;52:3116-20
77. Guzel O, Maresca A, Scozzafava A, et al. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv 3273. J Med Chem 2009;52:4063-7
78. Carta F, Maresca A, Suarez Covarrubias A, et al. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009;19:6649-54
79. Nishimori I, Minakuchi T, Maresca A, et al. The beta-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr Pharm Des 2010;16:3300-9
80. Buchieri MV, Riafrecha LE, Rodriguez OM, et al. Inhibition of the beta-carbonic anhydrases from Mycobacterium tuberculosis with C-cinnamoyl glycosides: identification of the first inhibitor with antimycobacterial activity. Bioorg Med Chem Lett 2013;23:740-3
81. Vullo D, Nishimori I, Scozzafava A, et al. Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides. Bioorg Med Chem Lett 2010;20:2178-82
82. Burghout P, Vullo D, Scozzafava A, et al. Inhibition of the beta-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: towards innovative drug design of antiinfectives ? Bioorg Med Chem 2011;19:243-8
83. Del Prete S, Isik S, Vullo D, et al. DNA cloning, characterization and inhibition studies of an alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem 2012;55:10742-8
84. Del Prete S, Isik S, Vullo D, et al. Anion inhibition studies of the alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Bioorg Med Chem Lett 2013;23:In press
85. Hall RA, Muhlschlegel FA. Fungal and nematode carbonic anhydrases: their inhibition in drug design. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. John Wiley & Sons, Hoboken; 2009 p. 301-2
86. Klengel T, Liang WJ, Chaloupka J, et al. Fungal adenylyl cyclase integrates CO2 sensing with cAMP signaling and virulence. Curr Biol 2005;15:2021-6
87. Mogensen EG, Janbon G, Chaloupka J, et al. Cryptococcus neoformans senses CO2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac. Eukaryot Cell 2006;5:103-11
88. Ohndorf UM, Schlicker C, Steegborn C. Crystallographic studies on carbonic anhydrases from fungal pathogens for structure-assisted drug development. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. John Wiley & Sons, Hoboken; 2009 p. 323-34
89. Schlicker C, Hall RA, Vullo D, et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol 2009;385:1207-20
90. Elleuche S, Poggeler S. Carbonic anhydrases in fungi. Microbiology 2010;156:23-9
91. Innocenti A, Leewattanapasuk W, Muhlschlegel FA, et al. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the pathogenic yeast Candida glabrata with anions. Bioorg Med Chem Lett 2009;19:4802-5
92. Cottier F, Leewattanapasuk W, Kemp LR, et al. Carbonic anhydrase regulation and CO2 sensing in the fungal pathogen Candida glabrata involves a novel Rca1p ortholog. Bioorg Med Chem 2013;23: In press
93. Isik S, Kockar F, Aydin M, et al. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. Bioorg Med Chem 2009;17:1158-63
94. Isik S, Kockar F, Arslan O, et al. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with anions. Bioorg Med Chem Lett 2008;18:6327-31
95. Hewitson KS, Vullo D, Scozzafava A, et al. Molecular cloning, characterization and inhibition studies of a beta-carbonic anhydrase from Malassezia globosa, a potential antidandruff target. J Med Chem 2012;55:3513-20
96. Hewitson KS, Supuran CT. Carbonic anhydrase inhibitors for treating dandruff and related disorders. WO061185; 2010
97. Isik S, Kockar F, Aydin M, et al. Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids. Bioorg Med Chem Lett 2009;19:1662-5
98. Innocenti A, Muhlschlegel FA, Hall RA, et al. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with simple anions. Bioorg Med Chem Lett 2008;18:5066-70
99. Innocenti A, Hall RA, Schlicker C, et al. Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. Bioorg Med Chem 2009;17:4503-9
100. Innocenti A, Hall RA, Schlicker C, et al. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylate. Bioorg Med Chem 2009;17:2654-7
101. Guzel O, Maresca A, Hall RA, et al. Carbonic anhydrase inhibitors. The betacarbonic anhydrases from the fungal pathogens Cryptococcus neoformans and Candida albicans are strongly inhibited by substituted-phenyl-1H-indole-5- sulfonamides. Bioorg Med Chem Lett 2010;20:2508-11
102. Cuesta-Seijo JA, Borchert MS, Navarro-Poulsen JC, et al. Structure of a dimeric fungal alpha-type carbonic anhydrase. FEBS Lett 2011;585:1042-8
103. Carta F, Innocenti A, Hall RA, et al. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic-/aromatic carboxylates and their derivatives. Bioorg Med Chem Lett 2011;21:2521-6
104. Pacchiano F, Carta F, Vullo D, et al. Inhibition of beta-carbonic anhydrases with ureido-substituted benzenesulfonamides. Bioorg Med Chem Lett 2010;20:102-5
105. De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117-29
106. Krungkrai J, Scozzafava A, Reungprapavut S, et al. Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action? Bioorg Med Chem 2005;13:483-9
107. Krungkrai J, Krungkrai SR, Supuran CT. Malarial parasite carbonic anhydrase and its inhibitors. Curr Top Med Chem 2007;7:909-17
108. Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malarial parasite and its inhibition. Curr Pharm Des 2008;14:631-40
109. Krungkrai J, Krungkrai SR, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/ heterocyclic sulfonamides: in vitro and in vivo studies. Bioorg Med Chem Lett 2008;18:5466-71
110. Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, sulfonamide and thiol inhibition studies of an alpha-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem 2013: In press